Stock Price, News, Quote and Profile of ERYTECH PHARMA - SPON ADR(NASDAQ:PHXM) stock

ERYTECH PHARMA - SPON ADR

NASDAQ:PHXM (9/28/2023, 7:07:12 PM)

4.74

-0.16 (-3.27%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)09-21 2023-09-21/amc

Earnings (Next)11-14 2023-11-14/amc

Ins OwnersN/A

Inst OwnersN/A

Market Cap287.95M

Shares60.75M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts42.22

IPO05-07 2013-05-07

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Erytech Pharma SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.

Company Info

ERYTECH PHARMA - SPON ADR

60 avenue Rockefeller

Lyon AUVERGNE-RHONE-ALPES

P: 33478744438.0

Employees: 49

Website: https://erytech.com/

PHXM News

9 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?

Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

10 days ago - ChartmillWhich stocks are moving on Tuesday?

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

10 days ago - ChartmillThese stocks are gapping in today's session

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.

10 days ago - ChartmillWondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.